Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats

References

• Agnoli C, Berrino F, Abagnato CA, Muti P, Panico S, Crosignani P, Krogh V. (2010). Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study. Nutr Metab Cardiovasc Dis 20:41–48.
   PubMed Web of Science ®Google Scholar
• Baker SD, Sparreboom A, Verweij J. (2006). Clinical pharmacokinetics of docetaxel: Recent developments. Clin Pharmacokinet 45:235–252.
   PubMed Web of Science ®Google Scholar
• Barré J, Chamouard JM, Houin G, Tillement JP. (1985). Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem 31:60–64.
   PubMed Web of Science ®Google Scholar
• Blonder JM, Baird L, Fulfs JC, Rosenthal GJ. (1999). Dose-dependent hyperlipidemia in rabbits following administration of poloxamer 407 gel. Life Sci 65:PL261–PL266.
   PubMed Web of Science ®Google Scholar
• Brocks DR, Ala S, Aliabadi HM. (2006). The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm Drug Dispos 27:7–16.
   PubMed Web of Science ®Google Scholar
• Chiou WL. (1978). Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level–time curve. J Pharmacokinet Biopharm 6:539–546.
   PubMedGoogle Scholar
• Choi YH, Suh JH, Lee JH, Cho IH, Lee MG. (2010). Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol 62:1084–1088.
   PubMed Web of Science ®Google Scholar
• Crommentuyn KM, Schellens JH, van den Berg JD, Beijnen JH. (1998). In-vitro metabolism of anti-cancer drugs, methods and applications: Paclitaxel, docetaxel, tamoxifen and ifosfamide. Cancer Treat Rev 24:345–366.
   PubMed Web of Science ®Google Scholar
• Eliot LA, Foster RT, Jamali F. (1999). Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm Res 16:309–313.
   PubMed Web of Science ®Google Scholar
• Fukushima K, Shibata M, Mizuhara K, Aoyama H, Uchisako R, Kobuchi S, Sugioka N, Takada K. (2009). Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats. Biomed Pharmacother 63:635–642.
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. (1982). Pharmacokinetics. 2nd ed. New York, USA: Marcel-Dekker.
   Google Scholar
• Gilbert DC, Parker C. (2005). Docetaxel for the treatment of prostate cancer. Future Oncol 1:307–314.
   Google Scholar
• Hammarsten J, Högstedt B. (2004). Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 13:47–55.
   PubMed Web of Science ®Google Scholar
• Johnston TP, Baker JC, Jamal AS, Hall D, Emeson EE, Palmer WK. (1999). Potential downregulation of HMG-CoA reductase after prolonged administration of P-407 in C57BL/6 mice. J Cardiovasc Pharmacol 34:831–842.
   PubMed Web of Science ®Google Scholar
• Johnston TP, Nguyen LB, Chu WA, Shefer S. (2001). Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. Int J Pharm 229:75–86.
   PubMed Web of Science ®Google Scholar
• Johnston TP, Palmer WK. (1993). Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol 46:1037–1042.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Alakhov VY. (2002). Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 54:759–779.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Miller DW. (2003). Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv Drug Deliv Rev 55:151–164.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee MG. (2008). Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 25:1915–1924.
   PubMed Web of Science ®Google Scholar
• Lee MG, Chiou WL. (1983). Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623–640.
   PubMedGoogle Scholar
• LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
   PubMed Web of Science ®Google Scholar
• Luke DR. (1992). Immunosuppressive effect of cyclosporine in the hyperlipidemic rat model. Biopharm Drug Dispos 13:635–645.
   Google Scholar
• Lyseng-Williamson KA, Fenton C. (2005). Docetaxel: A review of its use in metastatic breast cancer. Drugs 65:2513–2531.
   PubMed Web of Science ®Google Scholar
• Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. (1996). Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res 56:1296–1302.
   PubMed Web of Science ®Google Scholar
• McEntee M, Silverman JA, Rassnick K, Zgola M, Chan AO, Tau PT, Page RL. (2003). Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol 1:105–112.
   PubMedGoogle Scholar
• Mu CF, Balakrishnan P, Cui FD, Yin YM, Lee YB, Choi HG, Yong CS, Chung SJ, Shim CK, Kim DD. (2010). The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 31:2371–2379.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Deeg HJ, Yee GC. (1986). High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridaemia. Lancet 2:744–745.
   PubMed Web of Science ®Google Scholar
• Palmer WK, Emeson EE, Johnston TP. (1998). Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 136:115–123.
   PubMed Web of Science ®Google Scholar
• Porter CJ, Caliph SM, Charman WN. (1997). Differences in pre- and post-prandial plasma lipid profiles affect the extraction efficiency of a model highly lipophilic drug from beagle dog plasma. J Pharm Biomed Anal 16:175–180.
   Google Scholar
• Saloustros E, Georgoulias V. (2008). Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 8:1207–1222.
   PubMed Web of Science ®Google Scholar
• Shayeganpour A, Jun AS, Brocks DR. (2005). Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 26:249–257.
   PubMed Web of Science ®Google Scholar
• Shayeganpour A, Korashy H, Patel JP, El-Kadi AO, Brocks DR. (2008). The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat. Int J Pharm 361:78–86.
   PubMed Web of Science ®Google Scholar
• Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K. (1999). Interaction of docetaxel (“Taxotere”) with human P-glycoprotein. Jpn J Cancer Res 90:1380–1386.
   PubMedGoogle Scholar
• Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. (1998). Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9:1–17.
   PubMed Web of Science ®Google Scholar
• Urien S, Barré J, Morin C, Paccaly A, Montay G, Tillement JP. (1996). Docetaxel serum protein binding with high affinity to α1-acid glycoprotein. Invest New Drugs 14:147–151.
   PubMed Web of Science ®Google Scholar
• van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, Schinkel AH. (2009). Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 69:8996–9002.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. (1975). Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–390.
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. (1998). Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847.
   PubMed Web of Science ®Google Scholar
• Wout ZG, Pec EA, Maggiore JA, Williams RH, Palicharla P, Johnston TP. (1992). Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Parenter Sci Technol 46:192–200.
   PubMedGoogle Scholar
• Yan YD, Kim DH, Sung JH, Yong CS, Choi HG. (2010). Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Int J Pharm 399:116–120.
   PubMed Web of Science ®Google Scholar